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Syphilis has re-emerged as a significant public health threat in recent years. Whilst most cases of 
syphilis are currently diagnosed in low- and middle-income countries, the incidence of syphilis has 
been increasing in Western industrialised countries since the 1990s, particularly among gay, bisexual 
and other men who have sex with men (MSM).1 Increased rates among heterosexuals in these 
countries have also been reported in more recent years, most often in marginalised populations.2 In 
England, there were 7,982 diagnoses of syphilis during 2019, a 200% increase since 2010. Although 
three-quarters of cases were diagnosed in MSM, cases in heterosexual men and women have 
increased by 69% and 117%, respectively, between 2015 and 2019, and the number of cases of 
congenital syphilis (CS) has also increased.3 The underlying drivers of the increase in heterosexually 
acquired syphilis cases in England remain unclear. 
Syphilis is caused by Treponema pallidum subspecies pallidum and is typically transmitted by direct 
contact with an infectious lesion during sexual intercourse. The clinical presentation of syphilis is 
divided into three stages: primary, secondary, and tertiary, and the first two are the most infectious 
stages. Typically, primary syphilis presents as a painless ulcer (chancre) which usually occurs in 
genital sites and resolves within three to eight weeks. If left untreated, 25% of patients will develop 
secondary syphilis, a systemic disease characterised by fever, rash and lymphadenopathy. Secondary 
syphilis will resolve spontaneously in 3 to 12 weeks and all untreated cases will progress to latent 
(asymptomatic) infection, with one-third later developing features of tertiary syphilis.4  
In pregnancy, syphilis can be transmitted to the foetus at any stage. The risk of transplacental 
infection is 60-80% and is increased during the second half of pregnancy. Mother-to-child 
transmission is higher in untreated maternal primary or secondary syphilis (60-90%), decreasing to 
40% in early latent syphilis, and <10% in late latent syphilis. It is estimated that up to 40% of babies 
with congenital syphilis may be stillborn or die in the neonatal period.5 
In England, as in most industrialised countries, vertical transmission is rare, mainly because of the 
consistently high (>99%) uptake of antenatal syphilis screening.3 Additionally, early diagnosis and 
effective treatment of pregnant women with syphilis, especially in the first and second trimester, 
significantly reduces the risk of mother-to-child transmission, which in turn reduces the risk of 
adverse pregnancy outcomes, including stillbirths, perinatal deaths and congenital syphilis. 
Consequently, the incidence of congenital syphilis in the UK is below the World Health Organization 
elimination threshold (≤0.5/1000 live births). However, England has not had a robust surveillance 
system for CS and, therefore, the number of reported cases is likely to be underestimated. During 
2010-2017, 21 CS cases were identified; most were associated with mothers who were socially 
marginalised, had experienced difficulties accessing healthcare and had first presented to antenatal 
services close to the time of delivery.2,6  However, seven of these cases  were born to mothers who 
had had a negative first trimester antenatal screening test (‘screen-negative’ cases) and had, 
therefore, acquired syphilis later in pregnancy. Many of these mothers were UK-born and had no 
identifiable risk factors for syphilis. Some cases occurred in regions across England with recent 
increases in syphilis among women and MSM, suggesting that overlapping sexual networks may 
have facilitated wider dissemination.2  Crucially, in some of these CS cases, syphilis was not 
considered in the differential diagnosis of the unwell infant until relatively late in the investigations, 
as the clinicians were reassured by a negative antenatal screen.  
Current guidelines recommend that pregnant women identified as being at risk be re-screened in 
the third trimester, but it can be difficult to identify those at risk and routine third trimester 
screening for all pregnant women is unlikely to be cost-effective. It is, therefore, vital that obstetric 
and neonatal healthcare providers maintain a high index of suspicion throughout the antenatal and 
postnatal period. In one of the recent ‘screen negative’ cases in England, the mother presented in 
late pregnancy with genital ulcers, but syphilis was not considered by her healthcare provider.7 
In infants, manifestations of syphilis are classified as early congenital (birth to 2 years) and late 
congenital (after 2 years) and ranges from asymptomatic to multi-organ damage. However, the 
clinical presentation can be non-specific, especially during the early stages of illness, and overlaps 
with that of several other infections. Additionally, up to two-thirds of syphilitic infants may be 
asymptomatic at birth.5  
For infants with suspected congenital infection, we support the recommendation by Penner et al 
that the original ‘TORCH’ screen  (toxoplasmosis, ‘other’, rubella, cytomegalovirus, herpes simplex) 
which included syphilis under ‘other’, should be broadened to specifically emphasise syphilis testing:  
‘SCORTCH’ (syphilis, CMV, ‘other’, rubella, toxoplasmosis, chickenpox, HSV and blood borne viruses) 
.8 The diagnosis of syphilis can be confirmed by identification of T pallidum (by dark ground 
microscopy or PCR) in exudates from lesions or body fluids, as well as diagnostic blood tests (Table). 
Neonatal serology can be complicated by the presence of transplacentally-acquired maternal IgG 
antibodies. However, a neonatal nontreponemal antibody titre more than four times the maternal 
titre would support active infection because such a high ratio is unlikely to be achieved through 
passive transfer. Alternatively, a rising RPR titre over three months would also support a diagnosis of 
CS. Antibody assays for anti-treponemal IgM, which is not transferred across the placenta, are also 
useful.4 
Clinicians need to be aware that the serological response in infected neonates may not always be 
diagnostic; among the recent ‘screen-negative’ CS cases, many had a negative IgM and an RPR titre 
lower than that of their mother.9 This may be because the babies were infected late in 
pregnancy and were born prior to a mature antibody response developing, or they (or their mother 
prior to birth) had received empirical antibiotics which attenuated the antibody response. In such 
cases, a positive syphilis PCR would confirm the diagnosis; PCR of upper respiratory tract specimens 
such as nasopharyngeal aspirates, are particularly helpful and should be tested in all suspected CS 
cases.8 
Those with clinical disease or suggestive serological test results should have additional blood tests 
(full blood count, liver function tests, inflammatory markers), lumbar puncture (cell count, protein 
and treponemal and nontreponemal antibodies), long-bone x-rays, and other investigations as 
clinically indicated (e,g. ophthalmological review, hearing tests, neuroimaging).4 It is recommended 
that all cases of suspected CS should be discussed with a paediatrician with expertise in the diagnosis 
and management of congenital infection. 8 
In June 2019, Public Health England (PHE) published an Action Plan to address the increase in syphilis 
in England.3 The Action Plan emphasises the importance of controlling syphilis in MSM by increasing 
testing frequency among high-risk men and sustaining targeted health promotion. The plan also 
highlights the need for enhanced efforts to prevent CS by maintaining high antenatal screening 
coverage and improving vigilance for syphilis throughout antenatal care. PHE has commenced 
surveillance of maternal and congenital syphilis through the Infectious Diseases in Pregnancy 
Screening Programme’s Integrated Screening Outcomes Surveillance Service (ISOSS). Neonatologists 
and paediatricians are encouraged to report all cases directly to ISOSS.10  A better understanding of 
syphilis transmission leading to CS could lead to specific interventions to protect pregnant women 
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Serology tests should be performed on infant blood and maternal blood in parallel. 
(i) Treponemal tests, such as total antibody EIA and treponemal pallidum 
particle agglutination (TPPA) tests detect IgG as well as IgM, and may be 
positive due to passive transfer of maternal antibodies. A four-fold 
increase in titre within 3 months of birth, or positivity beyond 18 months 
of age, is consistent with CS. 
A positive IgM EIA is consistent with CS, as IgM is not transferred across 
the placenta.  
(ii) Non-treponemal tests, such as the VDRL or RPR, also detect both IgG and 
IgM antibodies. A four-fold RPR/VDRL titre above that of the mother, or a 
four-fold increase in titre within 3 months of birth, is consistent with CS. 
 




Direct demonstration of T pallidum by dark ground microscopy or PCR of exudates 
from lesions, body fluids e.g. nasal discharge, or naso-pharyngeal aspirate. 
Table. Investigations to confirm the diagnosis of congenital syphilis 
 
 
 
